Citius Pharmaceuticals, Inc. reported its financial results for the third quarter of fiscal year 2026, ending June 30, 2026, revealing a total revenue of $1.49 million for the quarter and $7.11 million for the nine-month period. This marks a significant milestone for the company, as it generated revenue for the first time from the commercial distribution of its oncology product, LYMPHIR, which began in December 2025. The gross profit for the quarter was approximately $1.00 million, reflecting a gross margin of about 67%, while the gross profit for the nine months was approximately $5.50 million, with a gross margin of 77%.
Comparatively, Citius Pharmaceuticals did not report any revenue in the same quarter of the previous year, indicating a substantial shift in its financial performance. However, the company also reported a net loss of $11.92 million for the quarter, an increase from the $9.20 million loss in the same period last year. For the nine-month period, the net loss was $49.42 million, up from $30.99 million in the prior year. The increase in losses was primarily attributed to higher operating expenses, which rose to $12.73 million for the quarter, compared to $8.79 million in the previous year, driven by increased general and administrative costs associated with the expansion of its commercial organization.
Citius Pharmaceuticals has made strategic advancements, including the expansion of its commercial team and the initiation of shipments of LYMPHIR to Europe, which is expected to enhance its market presence. The company has also entered into distribution agreements in various international markets, including Greece and Turkey, to facilitate access to LYMPHIR through Named Patient Programs. As of June 30, 2026, Citius had approximately 27.45 million shares of common stock outstanding, reflecting a reverse stock split executed in November 2024 to comply with Nasdaq listing requirements.
Operationally, the company has seen positive engagement metrics, with 83% of target accounts actively progressing LYMPHIR through formulary reviews and no reported reimbursement denials. Citius Oncology has also expanded its commercial organization, adding 21 field-based professionals and eight medical science liaisons to support clinical engagement. The company anticipates continued growth in orders and market acceptance of LYMPHIR, bolstered by ongoing clinical studies and a strong commercial supply chain.
Looking ahead, Citius Pharmaceuticals acknowledges the need for additional capital to support its operations beyond November 2026, as it continues to develop its product candidates and meet milestone obligations. The company is actively engaged in capital-raising initiatives and evaluating strategic alternatives to maximize shareholder value. However, it faces uncertainties regarding its ability to secure necessary funding and achieve regulatory approvals for its product candidates, which could materially impact its business operations and financial condition.
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals develops proprietary critical care and dermatological products, including Mino-Lok for catheter infection salvage, Halo-Lido for hemorrhoid relief, and NoveCite stem cell therapy for ARDS. The company focuses on reformulations of approved drugs with strong safety data, targeting large, underserved markets. It leverages regulatory exclusivity, innovative applications, and strategic licensing to provide effective, lower-risk therapeutic solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov